Find Obicetrapib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Ta-8995, 866399-87-3, Obicetrapib (free base), Amg-899, Dez-001, Obicetrapib [inn]
Molecular Formula
C32H31F9N4O5
Molecular Weight
722.6  g/mol
InChI Key
NRWORBQAOQVYBJ-GJZUVCINSA-N
FDA UNII
8O74K609HN

Obicetrapib
Obicetrapib is under investigation in clinical trial NCT02241772 (A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)).
1 2D Structure

Obicetrapib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-[2-[[3,5-bis(trifluoromethyl)phenyl]methyl-[(2R,4S)-1-ethoxycarbonyl-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2H-quinolin-4-yl]amino]pyrimidin-5-yl]oxybutanoic acid
2.1.2 InChI
InChI=1S/C32H31F9N4O5/c1-3-22-14-26(24-13-19(30(33,34)35)7-8-25(24)45(22)29(48)49-4-2)44(28-42-15-23(16-43-28)50-9-5-6-27(46)47)17-18-10-20(31(36,37)38)12-21(11-18)32(39,40)41/h7-8,10-13,15-16,22,26H,3-6,9,14,17H2,1-2H3,(H,46,47)/t22-,26+/m1/s1
2.1.3 InChI Key
NRWORBQAOQVYBJ-GJZUVCINSA-N
2.1.4 Canonical SMILES
CCC1CC(C2=C(N1C(=O)OCC)C=CC(=C2)C(F)(F)F)N(CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C4=NC=C(C=N4)OCCCC(=O)O
2.1.5 Isomeric SMILES
CC[C@@H]1C[C@@H](C2=C(N1C(=O)OCC)C=CC(=C2)C(F)(F)F)N(CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C4=NC=C(C=N4)OCCCC(=O)O
2.2 Other Identifiers
2.2.1 UNII
8O74K609HN
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Ta-8995

2.3.2 Depositor-Supplied Synonyms

1. Ta-8995

2. 866399-87-3

3. Obicetrapib (free Base)

4. Amg-899

5. Dez-001

6. Obicetrapib [inn]

7. 8o74k609hn

8. 866399-87-3 (free Base)

9. (2r,4s)-4-((3,5-bis(trifluoromethyl)benzyl)(5-(3-carboxypropoxy)pyrimidin-2-yl)amino)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2h-quinoline-1-carboxylic Acid Ethyl Ester

10. 1(2h)-quinolinecarboxylic Acid, 4-(((3,5-bis(trifluoromethyl)phenyl)methyl)(5-(3-carboxypropoxy)-2-pyrimidinyl)amino)-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, 1-ethyl Ester, (2r,4s)-

11. 1-ethyl (2r,4s)-4-[[[3,5-bis(trifluoromethyl)phenyl]methyl][5-(3-carboxypropoxy)-2-pyrimidinyl]amino]-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-1(2h)-quinolinecarboxylate

12. 4-((2-(((3,5-bis(trifluoromethyl)phenyl)methyl)((2r,4s)-1- (ethoxycarbonyl)-2-ethyl-6-(trifluoromethyl)-1,2,3,4- Tetrahydroquinolin-4-yl)amino)pyrimidin-5-yl)oxy)butanoic Acid

13. 4-((2-((3,5-bis(trifluoromethyl)benzyl)((2r,4s)-1-(ethoxycarbonyl)-2-ethyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-4-yl)amino)pyrimidin-5-yl)oxy)butanoic Acid

14. 4-[2-[[3,5-bis(trifluoromethyl)phenyl]methyl-[(2r,4s)-1-ethoxycarbonyl-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinolin-4-yl]amino]pyrimidin-5-yl]oxybutanoic Acid

15. Obicetrapib [who-dd]

16. Unii-8o74k609hn

17. Chembl3785197

18. Schembl17002081

19. Gtpl12205

20. Ex-a6112

21. Ta8995

22. Obicetrapib (amg-899,ta-8995)

23. Db14890

24. Ac-35552

25. Hy-18778

26. Q27270811

2.4 Create Date
2006-10-26
3 Chemical and Physical Properties
Molecular Weight 722.6 g/mol
Molecular Formula C32H31F9N4O5
XLogP37.4
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count17
Rotatable Bond Count12
Exact Mass722.21507356 g/mol
Monoisotopic Mass722.21507356 g/mol
Topological Polar Surface Area105 Ų
Heavy Atom Count50
Formal Charge0
Complexity1100
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

API SUPPLIERS

read-more
read-more

01

Angene International

United Kingdom

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Angene International

United Kingdom

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

02

Excenen PharmaTech

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Excenen PharmaTech

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

03

Glixx Laboratories

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Glixx Laboratories

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

04

Amadis Chemical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Amadis Chemical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

05

Excenen PharmaTech

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Excenen PharmaTech

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

06

BOC Sciences

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

BOC Sciences

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

07

Sunshine Chemical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Sunshine Chemical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Obicetrapib

About the Company : Amadis Chemical Company Limited has become a professional innovative chemical product manufacturer and a technical service provider. We're specialists in sales, manufacture, and ...

Amadis Chemical Company Limited has become a professional innovative chemical product manufacturer and a technical service provider. We're specialists in sales, manufacture, and service covering building block, key intermediate and API especially for the service of process development, pilot scale and manufacture. And the core products are Carbohydrates, Nucleosides, Nucleotides, Phosphonamidites, APIS and Pharmaceutical intermediates.
blank

02

Angene International

United Kingdom
AACR Annual meeting
Not Confirmed
arrow

Angene International

United Kingdom
arrow
AACR Annual meeting
Not Confirmed

Obicetrapib

About the Company : Angene is pledged to providing quality chemicals for use in research and development and commercial manufacturing. Angenes offers over 100,000 products including lab reagents, inte...

Angene is pledged to providing quality chemicals for use in research and development and commercial manufacturing. Angenes offers over 100,000 products including lab reagents, intermediates, bulk commodities, agro-chemicals, natural ingredients and active pharmaceutical ingredients (APIs). In addition to the 100,000+ products, Angene offers custom synthesis of chemicals that are not commercially available.
blank

03

BOC Sciences

U.S.A
AACR Annual meeting
Not Confirmed
arrow

BOC Sciences

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Obicetrapib

About the Company : BOC Sciences is a brand of BOCSCI Inc. We leverage our wide spectrum of business in the fields of development, manufacturing, marketing, and distribution to help you make best-info...

BOC Sciences is a brand of BOCSCI Inc. We leverage our wide spectrum of business in the fields of development, manufacturing, marketing, and distribution to help you make best-informed decisions tailored to your evolving needs for premium chemicals. Our complete suite of CRO services spans the entire molecule development pipeline including contract research for target identification, building blocks, compound synthesis, biochemical and cellular analysis, preclinical animal tests, and clinical studies.
blank

04

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Obicetrapib

About the Company : Founded by chemists with years of working experiences in famous CRO companies in China, Excenen Pharmatech experienced in organic chemistry expecially in medicinal chemistry resear...

Founded by chemists with years of working experiences in famous CRO companies in China, Excenen Pharmatech experienced in organic chemistry expecially in medicinal chemistry research/discovery fields. Excenen PharmaTech is dedicated to serve the pharmaceutical, scientific research and development industries for 10 years. During the past 10 years we supplied building blocks, small molecules, inhitbitors to world's leading companies like Janssen (Johnson&Johnson), Gilead, Abbvie..., Universities like Duke University, University of Chicago, University of Barcelona, University of Pécs etc.
blank

05

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Obicetrapib

About the Company : Founded by chemists with years of working experiences in famous CRO companies in China, Excenen Pharmatech experienced in organic chemistry expecially in medicinal chemistry resear...

Founded by chemists with years of working experiences in famous CRO companies in China, Excenen Pharmatech experienced in organic chemistry expecially in medicinal chemistry research/discovery fields. Excenen PharmaTech is dedicated to serve the pharmaceutical, scientific research and development industries for 10 years. During the past 10 years we supplied building blocks, small molecules, inhitbitors to world's leading companies like Janssen (Johnson&Johnson), Gilead, Abbvie..., Universities like Duke University, University of Chicago, University of Barcelona, University of Pécs etc.
blank

06

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Obicetrapib

About the Company : Glixx Laboratories Inc (Glixx) is a global leading company specializing in biological research chemicals, providing services to meet the needs of biomedical research markets. With ...

Glixx Laboratories Inc (Glixx) is a global leading company specializing in biological research chemicals, providing services to meet the needs of biomedical research markets. With its fast and efficient synthesis, the Glixx R&D team focuses on commercializing newly discovered research chemicals and bringing them to the life sciences R&D communities. Our company goal is to help our community by lowering the cost of the essential chemicals for research needs, to better progress on to new discoveries in drug development, medical screening, and all facets of scientific innovations.
blank

07

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Obicetrapib

About the Company : Sun-shine chemical has over 1,500m² of operation premises. The R&D laboratory is more than 1,000m² and is equipped with a variety of R&D laboratory equipment. The quality control...

Sun-shine chemical has over 1,500m² of operation premises. The R&D laboratory is more than 1,000m² and is equipped with a variety of R&D laboratory equipment. The quality control management laboratory is over 200m², equipped with high-efficient liquid chromatograph, digital melting point apparatus, digital polarimeter, UV spectrophotometer, etc. We have set up one kilogram-level intermediate laboratories, which may ensure growing customer demand and smooth commercial production. Sun-shine chemical is a reliable world supplier in fine chemicals and custom manufacturing.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1721586600,"product":"OBICETRAPIB-FOR TEST AND ANALYSIS PURPOSE ONLY","address":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK","city":"KURLA, MUMBAI","supplier":"NEWAMSTERDAM PHARMA","supplierCountry":"UNITED KINGDOM","foreign_port":"LONDON - HEATHROW","customer":"PIRAMAL PHARMA SOLUTIONS","customerCountry":"INDIA","quantity":"25.03","actualQuantity":"25.03","unit":"KGS","unitRateFc":"8187","totalValueFC":"227250.4","currency":"EUR","unitRateINR":"758933.6","date":"22-Jul-2024","totalValueINR":"18996108.1","totalValueInUsd":"227250.4","indian_port":"Bombay Air","hs_no":"29339990","bill_no":"4637516","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"LONDON - HEATHROW","supplierAddress":"GOOIMEER 2-351411 DC NAARDENSDNF NL","customerAddress":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK"}]
22-Jul-2024
22-Jul-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

TA-8995 (obicetrapib), CETP inhibitor, in combination with Ezetimibe, is being evaluated for the treatment of Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.


Lead Product(s): Obicetrapib,Ezetimibe

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: TA-8995

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: NewAmsterdam Pharma

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 16, 2024

blank

01

Menarini

Italy
arrow
AACR Annual meeting
Not Confirmed

Menarini

Italy
arrow
AACR Annual meeting
Not Confirmed

Details : TA-8995 (obicetrapib), CETP inhibitor, in combination with Ezetimibe, is being evaluated for the treatment of Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.

Product Name : TA-8995

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

December 16, 2024

blank

Details:

The net proceeds will be to advance the clinical development of TA-8995 (obicetrapib), which is being evaluated in the late-stage trial studies for the treatment of Atherosclerosis.


Lead Product(s): Obicetrapib

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: TA-8995

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Jefferies

Deal Size: $452.6 million Upfront Cash: Undisclosed

Deal Type: Public Offering December 13, 2024

blank

02

NewAmsterdam Pharma

Netherlands
arrow
AACR Annual meeting
Not Confirmed

NewAmsterdam Pharma

Netherlands
arrow
AACR Annual meeting
Not Confirmed

Details : The net proceeds will be to advance the clinical development of TA-8995 (obicetrapib), which is being evaluated in the late-stage trial studies for the treatment of Atherosclerosis.

Product Name : TA-8995

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

December 13, 2024

blank

Details:

TA-8995 (obicetrapib), CETP inhibitor, in combination with Ezetimibe, is being evaluated for the treatment of Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.


Lead Product(s): Obicetrapib,Ezetimibe

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: TA-8995

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 10, 2024

blank

03

NewAmsterdam Pharma

Netherlands
arrow
AACR Annual meeting
Not Confirmed

NewAmsterdam Pharma

Netherlands
arrow
AACR Annual meeting
Not Confirmed

Details : TA-8995 (obicetrapib), CETP inhibitor, in combination with Ezetimibe, is being evaluated for the treatment of Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.

Product Name : TA-8995

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

December 10, 2024

blank

Details:

NewAmsterdam TA-8995 (obicetrapib) is a CETP inhibitor combined with Ezetimibe, under evaluation in Phase III trials for Heterozygous Familial Hypercholesterolemia and cardiovascular disease.


Lead Product(s): Obicetrapib,Ezetimibe

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: TA-8995

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 03, 2024

blank

04

NewAmsterdam Pharma

Netherlands
arrow
AACR Annual meeting
Not Confirmed

NewAmsterdam Pharma

Netherlands
arrow
AACR Annual meeting
Not Confirmed

Details : NewAmsterdam TA-8995 (obicetrapib) is a CETP inhibitor combined with Ezetimibe, under evaluation in Phase III trials for Heterozygous Familial Hypercholesterolemia and cardiovascular disease.

Product Name : TA-8995

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

December 03, 2024

blank

Details:

TA-8995 (obicetrapib), CETP inhibitor, in combination with Ezetimibe, is being evaluated for the treatment of Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.


Lead Product(s): Obicetrapib,Ezetimibe

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: TA-8995

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 20, 2024

blank

05

NewAmsterdam Pharma

Netherlands
arrow
AACR Annual meeting
Not Confirmed

NewAmsterdam Pharma

Netherlands
arrow
AACR Annual meeting
Not Confirmed

Details : TA-8995 (obicetrapib), CETP inhibitor, in combination with Ezetimibe, is being evaluated for the treatment of Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.

Product Name : TA-8995

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

November 20, 2024

blank

Details:

The net proceeds will be to advance the clinical development of TA-8995 (obicetrapib), which is being evaluated in the late-stage trial studies for the treatment of Atherosclerosis.


Lead Product(s): Obicetrapib

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: TA-8995

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Jefferies

Deal Size: $416.5 million Upfront Cash: Undisclosed

Deal Type: Public Offering November 12, 2024

blank

06

NewAmsterdam Pharma

Netherlands
arrow
AACR Annual meeting
Not Confirmed

NewAmsterdam Pharma

Netherlands
arrow
AACR Annual meeting
Not Confirmed

Details : The net proceeds will be to advance the clinical development of TA-8995 (obicetrapib), which is being evaluated in the late-stage trial studies for the treatment of Atherosclerosis.

Product Name : TA-8995

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

November 12, 2024

blank

Details:

The net proceeds will be to advance the clinical development of TA-8995 (obicetrapib), which is being evaluated in the late-stage trial studies for the treatment of Atherosclerosis.


Lead Product(s): Obicetrapib

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: TA-8995

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Jefferies

Deal Size: $300.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering October 12, 2024

blank

07

NewAmsterdam Pharma

Netherlands
arrow
AACR Annual meeting
Not Confirmed

NewAmsterdam Pharma

Netherlands
arrow
AACR Annual meeting
Not Confirmed

Details : The net proceeds will be to advance the clinical development of TA-8995 (obicetrapib), which is being evaluated in the late-stage trial studies for the treatment of Atherosclerosis.

Product Name : TA-8995

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

October 12, 2024

blank

Details:

TA-8995 (obicetrapib), a next-generation, non statin, oral once-daily, low-dose CETP inhibitor. Currently being investigated in adult patients with a history of atherosclerotic cardiovascular disease.


Lead Product(s): Obicetrapib

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: TA-8995

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 04, 2024

blank

08

NewAmsterdam Pharma

Netherlands
arrow
AACR Annual meeting
Not Confirmed

NewAmsterdam Pharma

Netherlands
arrow
AACR Annual meeting
Not Confirmed

Details : TA-8995 (obicetrapib), a next-generation, non statin, oral once-daily, low-dose CETP inhibitor. Currently being investigated in adult patients with a history of atherosclerotic cardiovascular disease.

Product Name : TA-8995

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

September 04, 2024

blank

Details:

TA-8995 (obicetrapib), CETP inhibitor, in combination with Ezetimibe, is being evaluated for the treatment of Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.


Lead Product(s): Obicetrapib,Ezetimibe

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: TA-8995

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 07, 2024

blank

09

NewAmsterdam Pharma

Netherlands
arrow
AACR Annual meeting
Not Confirmed

NewAmsterdam Pharma

Netherlands
arrow
AACR Annual meeting
Not Confirmed

Details : TA-8995 (obicetrapib), CETP inhibitor, in combination with Ezetimibe, is being evaluated for the treatment of Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.

Product Name : TA-8995

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

August 07, 2024

blank

Details:

TA-8995 (obicetrapib) is a next-generation, non statin, oral once-daily, low-dose CETP inhibitor. It is currently being investigated in adult patients with Heterozygous Familial Hypercholesterolemia.


Lead Product(s): Obicetrapib

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: TA-8995

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: NewAmsterdam Pharma

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 26, 2024

blank

10

Menarini

Italy
arrow
AACR Annual meeting
Not Confirmed

Menarini

Italy
arrow
AACR Annual meeting
Not Confirmed

Details : TA-8995 (obicetrapib) is a next-generation, non statin, oral once-daily, low-dose CETP inhibitor. It is currently being investigated in adult patients with Heterozygous Familial Hypercholesterolemia.

Product Name : TA-8995

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

July 26, 2024

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Looking for 866399-87-3 / Obicetrapib API manufacturers, exporters & distributors?

Obicetrapib manufacturers, exporters & distributors 1

31

PharmaCompass offers a list of Obicetrapib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Obicetrapib manufacturer or Obicetrapib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Obicetrapib manufacturer or Obicetrapib supplier.

PharmaCompass also assists you with knowing the Obicetrapib API Price utilized in the formulation of products. Obicetrapib API Price is not always fixed or binding as the Obicetrapib Price is obtained through a variety of data sources. The Obicetrapib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Obicetrapib

Synonyms

Ta-8995, 866399-87-3, Obicetrapib (free base), Amg-899, Dez-001, Obicetrapib [inn]

Cas Number

866399-87-3

Unique Ingredient Identifier (UNII)

8O74K609HN

About Obicetrapib

Obicetrapib is under investigation in clinical trial NCT02241772 (A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)).

Obicetrapib Manufacturers

A Obicetrapib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Obicetrapib, including repackagers and relabelers. The FDA regulates Obicetrapib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Obicetrapib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Obicetrapib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Obicetrapib Suppliers

A Obicetrapib supplier is an individual or a company that provides Obicetrapib active pharmaceutical ingredient (API) or Obicetrapib finished formulations upon request. The Obicetrapib suppliers may include Obicetrapib API manufacturers, exporters, distributors and traders.

click here to find a list of Obicetrapib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Obicetrapib GMP

Obicetrapib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Obicetrapib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Obicetrapib GMP manufacturer or Obicetrapib GMP API supplier for your needs.

Obicetrapib CoA

A Obicetrapib CoA (Certificate of Analysis) is a formal document that attests to Obicetrapib's compliance with Obicetrapib specifications and serves as a tool for batch-level quality control.

Obicetrapib CoA mostly includes findings from lab analyses of a specific batch. For each Obicetrapib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Obicetrapib may be tested according to a variety of international standards, such as European Pharmacopoeia (Obicetrapib EP), Obicetrapib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Obicetrapib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty